রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন।
Indications:
BONDROVA 150MG is indicated for the treatment and prevention of osteoporosis in postmenopausal women at risk of fractures. It helps in maintaining bone density and reducing the risk of vertebral fractures.
Pharmacology:
BONDROVA contains Ibandronic Acid, a bisphosphonate that binds to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption. This action helps to maintain or increase bone mass and reduce the risk of fractures.
Dosage and Administration:
Dosage: 150 mg once a month, taken on the same date each month.
Administration:
Take with a full glass of plain water at least 60 minutes before food, beverages, or other medications.
Do not lie down for at least 60 minutes after taking the tablet.
Avoid taking with calcium or other mineral supplements within 2 hours of administration.
Interaction:
Avoid concurrent use with antacids or calcium supplements as they may reduce absorption.
Use caution with NSAIDs due to an increased risk of gastrointestinal irritation.
Contraindications:
Hypersensitivity to Ibandronic Acid or any component of the formulation.
Esophageal abnormalities, inability to stand or sit upright for at least 60 minutes.
Severe renal impairment (creatinine clearance <30 mL/min).
Side Effects:
Common: Dyspepsia, nausea, diarrhea, back pain.
Rare: Osteonecrosis of the jaw, atypical femoral fractures, or severe esophageal irritation.
Pregnancy & Lactation:
Pregnancy: Use during pregnancy is not recommended.
Lactation: It is unknown whether Ibandronic Acid is excreted in breast milk; use with caution in nursing mothers.
Precautions & Warnings:
Ensure adequate calcium and vitamin D intake during therapy.
Monitor renal function in patients with compromised kidney health.
Avoid in patients with active gastrointestinal ulcers or esophagitis.
Therapeutic Class:
Bisphosphonates.
Storage Conditions:
Store below 25°C in a dry place, protected from light and moisture.
Keep out of reach of children.